May 31, 2019

Anti-Dermatomycosis Skin Drugs Market 2025 Growth Analysis By Manufacturers, Regions, Type And Application, Forecast Analysis

Dermatomycosis is a type of skin disease majorly caused by the infection of different species of dermatophytes, yeast such as Candida species and Malassezia furfur or variety of fungi species like microsporum, genera trichophyton and epidermophyton. These organisms invade into the layer of skin and affect dermal appendices of hair, nails and epidermis. The condition is mainly characterized by colonization of the keratinized layers by these organisms on the surface of patient’s skin.

View Report:

These organisms have rigid cell wall and are complex in structure thus, anti-bacterial agents are not effective against organisms. Anti-dermatomycosis skin drugs like ketoconazole, clotrimazole and others are effectively used for the treatment of infection. These drugs are commonly used to treat conditions like ringworm, athlete’s foot and other systemic fungal infections like cryptococcal meningitis, and other types of infections. In addition, physical examination and microscopic examination of dermal lesions can be helpful to detect the disease condition.

The market of anti-dermatomycosis skin drugs is witnessing positive growth owing to the rise in fungal infections cases globally. World Health Organization (WHO) stated that nearly 20% of the world population is suffering from skin infections and the percentage is even higher in subtropical or tropical areas. In addition, good penetration and distribution of these drugs into hair folicles and horny layers will offer effective treatment in skin infection disorders and hence drives the market growth of anti-dermatomycosis skin drugs.

Request a Brochure of the Report @

However, less specific actions of anti-fungal drugs restrains the growth of global anti-dermatomycosis skin drugs market. In addition, high rate of side-effects like nausea, vomiting, constipation, hepatitis will restrain the market of anti-dermatomycosis skin drugs. In severe condition, adverse effects like renal toxicity, hypokalaemia, hepatic failure, anaphylactic shock can be developed. Thus, high rate of adverse effects, using these drugs will restrain the market growth of anti-dermatomycosis skin drugs. Additionally, high cost coupled with high rate of unwanted drug interactions of drugs will further restraint the market growth.

The global Anti-Dermatomycosis Skin Drugs market can be segmented on the basis of:

  • By Drug Category
  • Polyens
  • Amphotericin
  • Others
  • Azoles
  • Immidazoels
  • Ketoconazole
  • Sulconazole
  • Others
  • Triazoles
  • Fluconazole
  • Itraconazole
  • Others
  • Allylamines
  • Terbinafine
  • Others
  • Echinocandins
  • Caspofingin
  • Others
  • Other Anti Dermatomycosis Skin Drugs

Geographically, North America dominates the global anti-dermatomycosis skin drugs market. The growth of this market in North America is mainly attributed to increase incidence of skin infections. Europe is considered as the second largest region for global anti-dermatomycosis skin drugs market owing to increasing use of anti-dermatomycosis drugs. The market of anti-dermatomycosis skin drugs in Asia-Pacific region holds strong growth opportunities due to favorable climate condition for the development of skin infectious organisms. This factor would ultimately increase the number of patients seeking for the treatment of skin infections hence drives the market growth of anti-dermatomycosis skin drugs market. Additionally, countries like China and India are considered as the major market for anti-dermatomycosis skin drugs market owing to the high demand of these drugs among patient population which will eventually help Asia-Pacific region to grow steadily.

Request TOC @

The market of anti-dermatomycosis skin drugs is majorly dominated by the key players like Amplyx Pharmaceuticals, Inc., Vectura Group plc, Pfizer, Inc., AstraZeneca PLC, Eli Lilly and Company, Aparna Biosciences Corporation, Helix BioMedix, Inc., Aegera Therapeutics, Inc., Globeimmune, Inc. and others.